Please Wait

Applying Filters...

Technical details about Indium In 111 Oxyquinoline, learn more about the structure, uses, toxicity, action, side effects and more

Indium In 111 Oxyquinoline

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

1 Suppliers, 1 USDMF

DOSSIERs // Finished Dosage Forms

3 Dossiers, 2 FDA Orange Book, 1 Canada

RELATED EXCIPIENT COMPANIES

Suppliers, 6 Seppic, 3 Gangwal Chemicals, 2 Actylis, 1 Nanjing Bold Chemical, 1 Nanjing Well Pharmaceutical, 1 BioSpectra, 1 BASF, 1 Jai Radhe Sales

EXCIPIENTS BY APPLICATIONS

10 Solubilizers, 5 Parenteral, 4 Topical, 3 Emulsifying Agents, 2 Surfactant & Foaming Agents, 1 Co-Processed Excipients, 1 Film Formers & Plasticizers, 1 Direct Compression, 1 Rheology Modifiers, 1 API Stability Enhancers, 1 Thickeners and Stabilizers

DIGITAL CONTENT

1 News

1 News

1. Also known as: Indium in 111 oxyquinoline, 65389-08-4, Indium-111(3+);quinolin-8-olate, Indium in-111 oxine, Indium (111 in) oxyquinoline, Indium-111 oxine

Molecular Formula

C₂₇H₁₈InN₃O₃

Molecular Weight

543.4 g/mol

InChI Key

AEGSYIKLTCZUEZ-FZTWWWDYSA-K

Indium In 111 oxyquinoline (oxine) is a diagnostic radiopharmaceutical intended for radiolabeling of autologous leukocytes. It is composed of a 3:1 saturated complex of In-111 isotope and oxyquinoline. Indium-111 decays by isomeric transition and electron capture to cadmium-111, emitting a gamma ray that can be detected with a gamma ray camera. It is therefore useful in nuclear medicine, and is used in the labeling of leukocytes for localization of processes to which leukocytes migrate, such as those associated with abscesses or other infections. The degree of accuracy may vary with labeling techniques and with the size, location and nature of the inflammatory process. Following intravenous administration, the lipid-soluble complex is able to penetrate platelet cell membranes. Once inside, Indium detaches from the oxyquinoline complexes and becomes attached to cytoplasmic components.

1 2D Structure

2D Structure

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

indium-111(3+);quinolin-8-olate

2.1.2 InChI

InChI=1S/3C9H7NO.In/c3*11-8-5-1-3-7-4-2-6-10-9(7)8;/h3*1-6,11H;/q;;;+3/p-3/i;;;1-4

2.1.3 InChI Key

AEGSYIKLTCZUEZ-FZTWWWDYSA-K

2.1.4 Canonical SMILES

C1=CC2=C(C(=C1)[O-])N=CC=C2.C1=CC2=C(C(=C1)[O-])N=CC=C2.C1=CC2=C(C(=C1)[O-])N=CC=C2.[In+3]

2.1.5 Isomeric SMILES

C1=CC2=C(C(=C1)[O-])N=CC=C2.C1=CC2=C(C(=C1)[O-])N=CC=C2.C1=CC2=C(C(=C1)[O-])N=CC=C2.[111In+3]

2.2 Synonyms

2.2.1 Depositor-Supplied Synonyms

1. Indium In 111 Oxyquinoline

2. 65389-08-4

3. Indium-111(3+);quinolin-8-olate

4. Indium In-111 Oxine

5. Indium (111 In) Oxyquinoline

6. Indium-111 Oxine

7. Indium In111 Oxine

8. In-111 Oxyquinoline

9. Indium (in111) Oxine

10. Indium 111in Oxyquinoline

11. Indium (in111) Oxyquinoline

12. Indium Oxine In 111 (tn)

13. Indium-111 Oxyquinoline

14. Dtxsid70984005

15. Indium In 111 Oxyquinoline (usp)

16. Indium (111in) Oxyquinoline Solution

17. Db09473

18. D04526

2.3 Create Date

2005-08-08

3 Chemical and Physical Properties

Molecular Formula	C₂₇H₁₈InN₃O₃
Molecular Weight	543.4 g/mol
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	0
Exact Mass	543.03992 g/mol
Monoisotopic Mass	543.03992 g/mol
Topological Polar Surface Area	108 Å²
Heavy Atom Count	34
Formal Charge	0
Complexity	138
Isotope Atom Count	1
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	4

4 Drug and Medication Information

4.1 Drug Information

1 of 2
Drug Name	Indium in-111 oxyquinoline
Active Ingredient	Indium in-111 oxyquinoline
Dosage Form	Injectable
Route	Injection
Strength	1mci/ml
Market Status	Prescription
Company	Ge Healthcare

2 of 2
Drug Name	Indium in-111 oxyquinoline
Active Ingredient	Indium in-111 oxyquinoline
Dosage Form	Injectable
Route	Injection
Strength	1mci/ml
Market Status	Prescription
Company	Ge Healthcare

4.2 Drug Indication

Indium In 111 oxyquinoline is indicated for radiolabeling autologous leukocytes.

FDA Label

5 Pharmacology and Biochemistry

5.1 Absorption, Distribution and Excretion

Absorption

After injection of labeled leukocytes into normal volunteers, about 30% of the dose is taken up by spleen and 30% by liver, reaching a plateau at 2-48 hours after injection.

Route of Elimination

Elimination from the body of injected indium In 111 oxyquinoline is probably mainly through decay to stable cadmium since only a negligible amount (less than 1%) of the dose is excreted in feces and urine in 24 hours.

Clearance

Clearance from whole blood and biological distribution can vary considerably with the individual recipient, the condition of the injected cells and labeling techniques used. Clearance from liver and spleen, for the purpose of calculating the radiation dose, is assumed to be equal to the physical half-life of indium In 111 (67.2 hours).

5.2 Biological Half-Life

Indium In 111 decays by electron capture with a physical half-life of 67.2 hours (2.8 days). Between 9.5 to 24.4% of the injected dose remains in whole blood and clears with a biological half-time of 2.8 to 5.5 hours. The remainder (13-18%) clears from blood with a biological half-time of 64 to 116 hours.

5.3 Mechanism of Action

Indium-111 decays by isomeric transition and electron capture to cadmium-111, emitting a gamma ray that can be detected with a gamma ray camera. Following intravenous administration, the lipid-soluble complex is able to penetrate platelet cell membranes. Once inside, Indium detaches from the oxyquinoline complexes and becomes attached to cytoplasmic components.

POST ENQUIRY